发明名称 USP2a peptides and antibodies
摘要 The invention relates to novel USP2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment.
申请公布号 US9056919(B2) 申请公布日期 2015.06.16
申请号 US201213659173 申请日期 2012.10.24
申请人 NUCLEA BIOTECHNOLOGIES, INC. 发明人 Muraca Patrick J.
分类号 G01N33/573;C07K14/47;C07K16/40;C12N9/64;G01N33/574;C12Q1/68;G01N33/68;C12Q1/37;C07K7/08 主分类号 G01N33/573
代理机构 DT Ward, PC 代理人 Ward Donna T.;Jia Lingyun;DT Ward, PC
主权项 1. A method for staging or monitoring the progression of a disease associated with increased USP2a level in a subject which has said disease, the method comprising: a) obtaining a sample from the subject; b) contacting the sample with an anti-USP2a antibody mixture consisting of isolated antibodies that are specifically reactive with a USP2a peptide consisting of the amino acid sequence of SEQ ID NO. 1, or variants thereof, and isolated antibodies that are specifically reactive with a USP2a peptide consisting of the amino acid sequence of SEQ ID NO. 2, or variants thereof; c) determining a level of USP2a protein in the sample detected by said antibody mixture in an immunoassay; and d) comparing the level of the USP2a protein in the sample to a positive control baseline level of the USP2a protein, wherein a difference in the level of USP2a protein in the sample as compared to the positive control baseline level of greater than 20% overexpression is indicative of the stage or progression of said disease in the subject.
地址 Pittsfield MA US